Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics

The anti-CD20 antibody rituximab (RTX; Rituxan®, MabThera®) was the first anti-cancer antibody approved by the US Food and Drug Administration in 1997 and it is now the most-studied unconjugated therapeutic antibody. The knowledge gained over the past 15 y on the pharmacodynamics (PD) of this antibo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Golay, Josée, Semenzato, Gianpietro, Rambaldi, Alessandro, Foà, Robin, Gaidano, Gianluca, Gamba, Enrica, Pane, Fabrizio, Pinto, Antonello, Specchia, Giorgina, Zaja, Francesco, Regazzi, Mario
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2013
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3896596/
https://ncbi.nlm.nih.gov/pubmed/23933992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.26008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados